13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002013410
Total reported value
$750.4M
$750.4M
10 檔
84.7%
At the close of Q4 2025, Fcpm Iii Services B.v. disclosed equity holdings valued at approximately $750.4M, spread across 10 reported holdings.
In Q4 2025, Fcpm Iii Services B.v. displayed an active expansion posture, initiating 2 new positions and adding to 3 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 42.30% | -2.43% | -0.15% | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 14.01% | -0.27% | — | |
| 3 | ✓ | Engene Holdings Inc | Stock-Other | 11.40% | -6.86% | — | |
| 4 | RAPT | Rapt Therapeutics Inc | Stock-Other | 8.14% | — | +432.58% | |
| 5 | MPLT | Maplight Therapeutics Inc | Stock-Other | 7.43% | +6.33% | — | |
| 6 | VOR | Vor Biopharma Inc | Stock-Other | 6.20% | -0.07% | +852.84% | |
| 7 | REPL | Replimune Group Inc | Stock-Other | 3.58% | +1.17% | -32.46% | |
| 8 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 3.22% | -0.27% | +0.47% | |
| 9 | ✓ | Crescent Biopharma Inc. | Stock-Other | 2.61% | -0.25% | — | |
| 10 | ✓ | Engene Holdings Inc | Stock-Other | 1.12% | -0.90% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RAPT | Rapt Therapeutics Inc | +6.4% | +432.58% | Add |
| 2 | VOR | Vor Biopharma Inc | +2.5% | +852.84% | Add |
| 3 | ✓ | Engene Holdings Inc | +0.7% | — | Unchanged |
| 4 | DYN | Dyne Therapeutics Inc | +0.2% | — | Unchanged |
| 5 | REPL | Replimune Group Inc | +0.1% | -32.46% | Trim |
| 6 | ✓ | Engene Holdings Inc | -1.8% | — | Unchanged |
| 7 | BCYC | Bicycle Therapeutics Plc-adr | -2.1% | +0.47% | Add |
| 8 | NAMS | NewAmsterdam Pharma Company N.V. | -10.1% | -0.15% | Trim |
| 9 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 10 | CATBUSD | Astria Therapeutics Inc | — | EXIT | Sold out |
| 11 | ✓ | Crescent Biopharma Inc. | — | NEW | New buy |
According to official SEC Form 13F filings, Fcpm Iii Services B.v. reported a total U.S. public equity portfolio value of $750.4M across 10 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NAMS, DYN, ENGENE HOLDINGS INC) accounted for 84.7% of total reported equity market value during Q4 2025.
Top New Position Initiated
MPLT
市值: $56.7M
Top Position Liquidated / Trimmed
CATBUSD
前期市值: $29.9M
During Q4 2025, Fcpm Iii Services B.v.'s top holdings by market value included NAMS (42.3%)、DYN (14.0%)、ENGENE HOLDINGS INC (11.4%). The largest single position, NAMS, represented 42.3% of total portfolio value.
In Q4 2025, Fcpm Iii Services B.v. made 8 total portfolio adjustments, initiating 2 new buys, adding to 3 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.